TAM 疗法：从癌症耐药到癌症耐药性缓解。

TAM-tastic: from resistance to resilience in cancer.

机构信息

Department of Fundamental Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.

出版信息

Trends Pharmacol Sci. 2024 Nov;45(11):953-954. doi: 10.1016/j.tips.2024.09.006. Epub 2024 Oct 1.

DOI:10.1016/j.tips.2024.09.006

PMID:39358174

Abstract

Overcoming resistance to immunotherapy in cancer is challenging due, in part, to tumor-associated macrophages (TAMs) co-expressing T cell immunoglobulin and mucin domain-containing 3 (TIM3) and V-domain immunoglobulin suppressor of T cell activation (VISTA) in tumor microenvironments (TME) with sparse T cell infiltration. In a recent article, Vanmeerbeek et al. found that blocking TIM3 or VISTA on IL-4-supported TAMs, in combination with paclitaxel (PTX), reprogrammed TAMs to attack cancer cells, highlighting a potential new therapeutic strategy.

摘要

克服癌症免疫疗法的耐药性具有挑战性，部分原因是肿瘤相关巨噬细胞（TAMs）在肿瘤微环境（TME）中共同表达 T 细胞免疫球蛋白和粘蛋白结构域 3（TIM3）和 V 结构域免疫球蛋白 T 细胞活化抑制剂（VISTA），TME 中 T 细胞浸润稀疏。在最近的一篇文章中，Vanmeerbeek 等人发现，阻断 IL-4 支持的 TAMs 上的 TIM3 或 VISTA，与紫杉醇（PTX）联合使用，可重新编程 TAMs 攻击癌细胞，这突显了一种潜在的新治疗策略。